RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company that is pioneering the use of robotics and flexible instruments to improve minimally invasive surgery, today announced the appointment of William N. Kelley, M.D. to serve on its Board of Directors. The appointment will be effective January 1, 2015, and increases the size of the TransEnterix Board of Directors to nine members. The Board of Directors determined that Dr. Kelley is an independent director.

"We are delighted to welcome Dr. Kelley to the TransEnterix Board of Directors. Dr. Kelley is a recognized leader in the medical community, has broad health care experience and will be a tremendous asset to our Board of Directors," said Todd M. Pope, President and CEO of TransEnterix. "As we continue to work toward a mid-2015 submission of the 510(k) application for our SurgiBot™ system and commercialization thereafter, we are confident that Dr. Kelley will bring great value as we execute our strategy."

"I am excited to be joining the TransEnterix Board of Directors," commented Dr. Kelley. "TransEnterix' patient-side SurgiBot system can address a significant unmet need in surgical robotics, and I am impressed by TransEnterix' strong culture of innovation."

Dr. Kelley has over 40 years of health care experience including health care system management, education and research, and currently serves as Professor of Medicine in the Perelman School of Medicine at the University of Pennsylvania. His past experience includes serving as Executive Vice President of the University of Pennsylvania with responsibilities as Chief Executive Officer for the Medical Center, Dean of the School of Medicine, and the Robert G. Dunlop Professor of Medicine and Biochemistry and Biophysics. Dr. Kelley has also served as President of the American Society for Clinical Investigation, President of the American College of Rheumatology, Chair of the American Board of Internal Medicine, and Chair of the Residency Review Committee for Internal Medicine. Dr. Kelley currently serves on the Board of Directors of GenVec, Inc., and previously served on the Board of Directors of Merck & Co. Inc., Beckman Coulter, Inc., Advanced Biosurfaces, Inc. and Polymedix, Inc. Dr. Kelley has served on the editorial boards of 13 medical journals, and his bibliography includes more than 300 publications and 17 books. Dr. Kelley received his medical degree from Emory University.

With this appointment, the TransEnterix Board of Directors will consist of Paul LaViolette, TransEnterix' Chairman of the Board, Todd M. Pope, TransEnterix' President and CEO, Dennis Dougherty, Managing General Partner of Intersouth Partners, Jane H. Hsiao, Ph.D., Vice-Chairman and Chief Technical Officer of OPKO Health, Inc., Aftab R. Kherani, M.D., Partner of Aisling Capital, David Milne, Managing Partner of SV Life Science Advisors, Richard C. Pfenniger, Jr., former Chairman, CEO and President of Continucare Corporation, William Starling, Managing Director, Synergy Life Science Partners and Dr. Kelley.

About TransEnterix

TransEnterix is a medical device company that is pioneering the use of robotics and flexible instruments to improve minimally invasive surgery. The company is focused on the development and commercialization of the SurgiBot™ system, a minimally invasive surgical robotic system that allows the surgeon to be patient-side within the sterile field. For more information, visit the company's website at www.transenterix.com.

Forward Looking Statements

This press release includes statements relating to the SurgiBot system, our flexible energy device and our current regulatory and commercialization plans for these products. These statements and other statements regarding our future plans and goals constitute "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations, including whether we will successfully submit our SurgiBot system regulatory filings in mid-2015, and whether we will be able to commercialize the SurgiBot system. Factors that could cause our results to differ materially from those described include, but are not limited to, whether the SurgiBot system's 510(k) application(s) will be cleared by the U.S. FDA, and whether Dr. Kelley will be an asset to the Board of Directors and bring great value as we execute our strategy. For a discussion of the most significant risks and uncertainties associated with TransEnterix's business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2013 filed on March 5, 2014 as amended, and other filings we make with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward looking statement, whether as a result of new information, future events or otherwise.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20141211005118/en/

WestWicke
Mark Klausner, 443-213-0501
transenterix@westwicke.com
or
TransEnterix
Mohan Nathan, 919-917-6559
mnathan@transenterix.com

Source: TransEnterix, Inc.

News Provided by Acquire Media